Prothena Corporation plc
Prothena Corp. Public Ltd Co. is an Irish-domiciled clinical-stage biotechnology company focused on protein dysregulation and misfolded-protein biology. Its pipeline includes antibody-based programs for neurodegenerative and rare amyloid diseases, with development activities spanning Parkinson’s disease, ATTR amyloidosis, Alzheimer’s disease, ALS, and related disorders.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueWholly owned and partnered therapeutic antibodies in clinical development.
Revenue from partnered development work, milestones, and license arrangements.
Products
Reported · share of revenue- Collaboration99.5 %
- License0.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Prothena’s direct customers are pharmaceutical and biotechnology partners that fund or co-develop its programs, rather than end-patient buyers. Its collaboration model also depends on future healthcare payers and providers if any candidate reaches commercialization, because reimbursement and adoption would determine market access.
Companies such as Roche, BMS, and Novo Nordisk that license programs, fund development, or share commercialization rights.
Partners that support clinical trials, target discovery, or regional commercialization of specific assets.
Neurology, cardiology, and specialty treatment centers that would prescribe approved therapies.
Public and private payers that would determine coverage and access for any approved product.
Strategy
Prothena’s strategy is to advance a small number of high-science programs through clinical development and use partnerships to share cost, expertise, and commercialization reach. It also evaluates whether to self-commercialize, co-promote, license regionally, or out-license each asset depending on the program and market opportunity.
Clinical progress is the main driver of value creation in a biotech without marketed products.
Different assets may require different launch models, from co-promotion to out-licensing.
The company’s scientific edge comes from targeting misfolded proteins across CNS and peripheral diseases.
Geography
Prothena is headquartered in Ireland and listed on Nasdaq in the United States, while its research, development, and partner relationships are international. Its business is concentrated in global clinical development rather than manufacturing, and it relies on third-party CROs, manufacturers, and collaborators across multiple countries.
Risks
Prothena faces the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and dependence on external funding and partners. Its revenue is collaboration-based and can be volatile, while future commercialization would also depend on reimbursement, manufacturing, intellectual property protection, and third-party execution.
- Clinical development failureImpact: CriticalLikelihood: High
Pipeline value depends on proving safety and efficacy in human trials, which is inherently uncertain.
Exposure - Capital and liquidity riskImpact: HighLikelihood: High
The company expects ongoing R&D spend before any product sales, so financing needs can persist.
Exposure: clinical-stage operations and trial expansion
- Dependence on collaboration partnersImpact: HighLikelihood: Medium
A large share of activity and revenue is tied to partners that control or influence development and manufacturing.
Exposure - Intellectual property riskImpact: HighLikelihood: Medium
Biotech value depends on patent scope, enforceability, and freedom to operate.
Exposure - Reimbursement and commercialization riskImpact: MediumLikelihood: Medium
Even approved therapies may not gain broad access without payer coverage and adequate pricing.
Exposure: future Parkinson’s and amyloid products
Accounting
Judgemental itemsRevenue depends on estimating performance obligations under Roche and BMS agreements, affecting timing and volatility.
Impact: Can shift revenue between quarters and years
Unrecognized amounts tied to remaining obligations must be tracked until work is completed.
Impact: Affects future revenue recognition visibility
A meaningful non-cash expense in biotech, affecting operating loss and comparability.
Impact: Impacts reported R&D and G&A expense
Clinical and preclinical assets are typically expensed, and any capitalized intangibles require judgment on recoverability.
Impact: Can affect asset values and loss recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
NuCana plc
NCNA · Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform.
Last updated: 24/09/2026